Ocular distribution of the chimeric protein IL2-PE40

David Benezra*, Genia Maftzir, Ella Hochberg, Irene Anteby, Haya Lorberboum-Galski

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


A construct of IL-2 and pseudomonas exotoxin (PE40) has been genetically engineered. An aliquot of 100 μ1 of the chimeric protein, radiolabelled with I125, was administered to healthy rats by various routes. At different intervals, ocular and non ocular tissues were removed and the levels of the radiolabelled chimeric protein IL2-PE40 measured. Systemic administration of IL2-PE40 either intravenously (IV) or intraperitoneally (IP) leads to high levels of the drug in the blood, liver and spleen. Little or no radioactivity is observed within the ocular tissues using this route. On the other hand, local administration of the drug either as subtenon injection or as eye drops resulted in a very high concentration of the drug within the conjunctiva, cornea and sclera, with little radioactivity detected systemically. Subtenon injection induced a significant drug level within the optic nerve. With the drops, the chimeric protein was also detected, in low levels, intraocularly.

Original languageAmerican English
Pages (from-to)153-158
Number of pages6
JournalCurrent Eye Research
Issue number2
StatePublished - 1995


  • Autoimmunity
  • Chimeric protein
  • Eye
  • IL-2
  • PE40
  • Rat


Dive into the research topics of 'Ocular distribution of the chimeric protein IL2-PE40'. Together they form a unique fingerprint.

Cite this